Humoral and cellular immunogenicity of COVID-19 booster dose vaccination in inflammatory arthritis patients

Can patients with rheumatic diseases respond differently to a booster dose of COVID-19 vaccines than healthy controls? Polish scientists investigated the humoral and cellular responses in patients with inflammatory rheumatic diseases treated with immunosuppressants. It turned out that patients had a significantly reduced humoral and cellular response after the booster dose compared to the healthy group. The obtained results may translate into a recommendation for further vaccinations against COVID-19 for rheumatic patients with impaired immunity. The manuscript was published in Frontiers in Immunology.